 Samuel Dominguez
Concepts (723)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 27 | 2025 | 173 | 7.610 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 21 | 2026 | 94 | 5.030 |
Why?
| | Respiratory Tract Infections | 24 | 2025 | 395 | 4.950 |
Why?
| | Enterovirus D, Human | 17 | 2025 | 87 | 4.370 |
Why?
| | Multiplex Polymerase Chain Reaction | 12 | 2025 | 54 | 4.290 |
Why?
| | Myelitis | 14 | 2025 | 107 | 3.810 |
Why?
| | Disease Outbreaks | 23 | 2025 | 426 | 3.560 |
Why?
| | Polymerase Chain Reaction | 15 | 2026 | 1049 | 3.180 |
Why?
| | Molecular Diagnostic Techniques | 11 | 2026 | 104 | 3.100 |
Why?
| | Child, Preschool | 85 | 2026 | 11837 | 2.740 |
Why?
| | Enterovirus | 11 | 2019 | 83 | 2.730 |
Why?
| | Meningitis | 8 | 2022 | 80 | 2.620 |
Why?
| | Coronavirus | 10 | 2015 | 47 | 2.610 |
Why?
| | Pleural Effusion | 3 | 2026 | 59 | 2.570 |
Why?
| | Central Nervous System Viral Diseases | 7 | 2025 | 78 | 2.560 |
Why?
| | Infant | 72 | 2026 | 10064 | 2.560 |
Why?
| | Child | 111 | 2026 | 22680 | 2.550 |
Why?
| | Influenza, Human | 13 | 2023 | 623 | 2.450 |
Why?
| | Neuromuscular Diseases | 7 | 2025 | 146 | 2.380 |
Why?
| | Anti-Bacterial Agents | 20 | 2026 | 1953 | 2.330 |
Why?
| | Encephalitis | 11 | 2022 | 142 | 2.190 |
Why?
| | Gastroenteritis | 5 | 2023 | 63 | 2.040 |
Why?
| | Clostridium Infections | 6 | 2024 | 74 | 2.020 |
Why?
| | Anti-Infective Agents | 5 | 2022 | 244 | 1.990 |
Why?
| | Immunoglobulins, Intravenous | 7 | 2026 | 133 | 1.990 |
Why?
| | Colorado | 41 | 2025 | 4572 | 1.820 |
Why?
| | Influenza A Virus, H1N1 Subtype | 7 | 2020 | 158 | 1.760 |
Why?
| | Bacteremia | 4 | 2025 | 223 | 1.760 |
Why?
| | Diarrhea | 7 | 2023 | 194 | 1.630 |
Why?
| | Feces | 9 | 2023 | 514 | 1.620 |
Why?
| | Blood Culture | 2 | 2025 | 27 | 1.570 |
Why?
| | Paralysis | 4 | 2018 | 69 | 1.510 |
Why?
| | Hospitals, Pediatric | 13 | 2025 | 557 | 1.510 |
Why?
| | Coronavirus Infections | 9 | 2020 | 383 | 1.440 |
Why?
| | Humans | 175 | 2026 | 145491 | 1.430 |
Why?
| | Bacteria | 8 | 2025 | 897 | 1.420 |
Why?
| | Infliximab | 5 | 2026 | 111 | 1.420 |
Why?
| | Nervous System Diseases | 5 | 2020 | 287 | 1.410 |
Why?
| | Community-Acquired Infections | 6 | 2026 | 177 | 1.400 |
Why?
| | Bacteriological Techniques | 2 | 2025 | 68 | 1.390 |
Why?
| | Antimicrobial Stewardship | 3 | 2025 | 130 | 1.340 |
Why?
| | Central Nervous System Infections | 2 | 2022 | 35 | 1.300 |
Why?
| | Streptococcus pneumoniae | 4 | 2025 | 180 | 1.300 |
Why?
| | Respiratory Syncytial Virus, Human | 4 | 2025 | 81 | 1.280 |
Why?
| | Simplexvirus | 3 | 2020 | 82 | 1.270 |
Why?
| | Male | 112 | 2026 | 72817 | 1.250 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2025 | 139 | 1.220 |
Why?
| | Cerebrospinal Fluid | 6 | 2019 | 88 | 1.220 |
Why?
| | Epidemiological Monitoring | 4 | 2025 | 70 | 1.140 |
Why?
| | Streptococcus pyogenes | 3 | 2025 | 41 | 1.130 |
Why?
| | Sequence Analysis, DNA | 9 | 2026 | 831 | 1.120 |
Why?
| | Retrospective Studies | 42 | 2026 | 17269 | 1.100 |
Why?
| | Pandemics | 12 | 2025 | 1706 | 1.090 |
Why?
| | Stevens-Johnson Syndrome | 3 | 2017 | 37 | 1.080 |
Why?
| | Female | 94 | 2026 | 78763 | 1.080 |
Why?
| | Streptococcal Infections | 3 | 2025 | 171 | 1.060 |
Why?
| | Chiroptera | 4 | 2014 | 62 | 1.040 |
Why?
| | Adolescent | 50 | 2025 | 22485 | 1.020 |
Why?
| | Bacterial Infections | 2 | 2020 | 247 | 1.020 |
Why?
| | Haemophilus influenzae | 2 | 2024 | 67 | 1.020 |
Why?
| | Child, Hospitalized | 3 | 2024 | 54 | 1.010 |
Why?
| | Osteomyelitis | 4 | 2026 | 144 | 1.010 |
Why?
| | Nasopharynx | 5 | 2023 | 73 | 1.010 |
Why?
| | Intensive Care Units, Pediatric | 4 | 2021 | 288 | 1.000 |
Why?
| | Sensitivity and Specificity | 12 | 2026 | 2002 | 0.990 |
Why?
| | Spike Glycoprotein, Coronavirus | 8 | 2022 | 130 | 0.990 |
Why?
| | Picornaviridae Infections | 5 | 2019 | 53 | 0.970 |
Why?
| | Specimen Handling | 2 | 2026 | 189 | 0.970 |
Why?
| | Otitis Media | 3 | 2024 | 181 | 0.960 |
Why?
| | Empyema | 1 | 2026 | 8 | 0.940 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2026 | 33 | 0.910 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2025 | 27 | 0.880 |
Why?
| | Respiratory Tract Diseases | 2 | 2024 | 176 | 0.880 |
Why?
| | Communicable Diseases | 2 | 2017 | 166 | 0.860 |
Why?
| | Infant, Newborn | 20 | 2025 | 6437 | 0.850 |
Why?
| | Conjunctivitis, Bacterial | 1 | 2024 | 12 | 0.850 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2025 | 58 | 0.830 |
Why?
| | Trachea | 1 | 2026 | 258 | 0.830 |
Why?
| | Staphylococcus aureus | 2 | 2025 | 455 | 0.820 |
Why?
| | Pneumonia, Bacterial | 1 | 2025 | 113 | 0.800 |
Why?
| | Cross Infection | 4 | 2025 | 264 | 0.800 |
Why?
| | RNA, Viral | 11 | 2020 | 693 | 0.780 |
Why?
| | Hospitalization | 15 | 2024 | 2458 | 0.780 |
Why?
| | Coronary Vessels | 3 | 2026 | 247 | 0.770 |
Why?
| | Antiviral Agents | 6 | 2020 | 772 | 0.770 |
Why?
| | Pneumonia, Mycoplasma | 3 | 2024 | 55 | 0.770 |
Why?
| | Coronaviridae | 2 | 2014 | 4 | 0.750 |
Why?
| | Parechovirus | 3 | 2019 | 8 | 0.740 |
Why?
| | Immunologic Factors | 2 | 2026 | 260 | 0.710 |
Why?
| | Drug Resistance, Bacterial | 3 | 2022 | 206 | 0.700 |
Why?
| | Respiration, Artificial | 2 | 2026 | 712 | 0.680 |
Why?
| | Diagnostic Tests, Routine | 2 | 2019 | 107 | 0.680 |
Why?
| | Nervous System Malformations | 1 | 2022 | 46 | 0.680 |
Why?
| | Virus Cultivation | 2 | 2018 | 31 | 0.670 |
Why?
| | Rhinovirus | 5 | 2017 | 60 | 0.670 |
Why?
| | Enteropathogenic Escherichia coli | 1 | 2020 | 1 | 0.660 |
Why?
| | Enterotoxigenic Escherichia coli | 1 | 2020 | 6 | 0.660 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 44 | 0.660 |
Why?
| | Acute Disease | 12 | 2025 | 1040 | 0.650 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.640 |
Why?
| | Hospitals | 4 | 2021 | 732 | 0.630 |
Why?
| | Adenoviridae Infections | 2 | 2023 | 20 | 0.630 |
Why?
| | Escherichia coli Infections | 1 | 2020 | 126 | 0.610 |
Why?
| | Acyclovir | 1 | 2020 | 97 | 0.610 |
Why?
| | Serratia Infections | 1 | 2019 | 8 | 0.600 |
Why?
| | Serratia marcescens | 1 | 2019 | 17 | 0.600 |
Why?
| | Drug Utilization | 2 | 2017 | 167 | 0.590 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2019 | 26 | 0.590 |
Why?
| | Pneumonia | 1 | 2025 | 632 | 0.590 |
Why?
| | Herpesvirus 6, Human | 2 | 2019 | 14 | 0.590 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 37 | 0.590 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2026 | 251 | 0.590 |
Why?
| | Receptors, Virus | 3 | 2017 | 96 | 0.580 |
Why?
| | Seasons | 10 | 2023 | 559 | 0.580 |
Why?
| | Microbial Sensitivity Tests | 4 | 2026 | 378 | 0.580 |
Why?
| | Syringes | 1 | 2019 | 49 | 0.580 |
Why?
| | Equipment Contamination | 1 | 2019 | 71 | 0.580 |
Why?
| | Neisseriaceae Infections | 1 | 2018 | 6 | 0.580 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 46 | 0.570 |
Why?
| | Kingella kingae | 1 | 2018 | 12 | 0.570 |
Why?
| | Steroids | 1 | 2019 | 160 | 0.570 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 389 | 0.570 |
Why?
| | Adenoviridae | 3 | 2023 | 199 | 0.560 |
Why?
| | Enterovirus A, Human | 1 | 2018 | 13 | 0.560 |
Why?
| | Herpes Simplex | 2 | 2018 | 98 | 0.560 |
Why?
| | Fluoxetine | 1 | 2018 | 56 | 0.550 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2017 | 27 | 0.530 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 221 | 0.530 |
Why?
| | Escherichia coli | 2 | 2025 | 857 | 0.510 |
Why?
| | Staphylococcal Infections | 3 | 2026 | 391 | 0.490 |
Why?
| | Time Factors | 10 | 2021 | 7171 | 0.470 |
Why?
| | Osteoarthritis | 1 | 2018 | 200 | 0.470 |
Why?
| | Viral Tropism | 2 | 2015 | 36 | 0.470 |
Why?
| | Viruses | 5 | 2022 | 168 | 0.470 |
Why?
| | Molecular Epidemiology | 2 | 2017 | 73 | 0.470 |
Why?
| | Mycoplasma pneumoniae | 3 | 2024 | 53 | 0.460 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 45 | 0.460 |
Why?
| | Catheter-Related Infections | 1 | 2016 | 96 | 0.450 |
Why?
| | Phylogeny | 9 | 2016 | 1028 | 0.450 |
Why?
| | Case-Control Studies | 9 | 2024 | 3619 | 0.450 |
Why?
| | Adenovirus Infections, Human | 1 | 2015 | 15 | 0.450 |
Why?
| | Bacterial Typing Techniques | 1 | 2015 | 44 | 0.450 |
Why?
| | Coronary Aneurysm | 3 | 2026 | 19 | 0.440 |
Why?
| | Calcitonin | 1 | 2015 | 27 | 0.440 |
Why?
| | Caliciviridae Infections | 1 | 2015 | 18 | 0.440 |
Why?
| | Genome, Viral | 3 | 2016 | 218 | 0.440 |
Why?
| | Rotavirus Infections | 1 | 2015 | 37 | 0.440 |
Why?
| | Muscle Hypotonia | 1 | 2015 | 33 | 0.440 |
Why?
| | Cohort Studies | 10 | 2024 | 5992 | 0.440 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2020 | 437 | 0.430 |
Why?
| | United States | 22 | 2026 | 16115 | 0.430 |
Why?
| | Pneumonia, Pneumococcal | 2 | 2025 | 47 | 0.430 |
Why?
| | Prospective Studies | 9 | 2025 | 8039 | 0.430 |
Why?
| | Catheterization, Central Venous | 1 | 2016 | 124 | 0.430 |
Why?
| | Virus Diseases | 2 | 2025 | 218 | 0.420 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.420 |
Why?
| | Coronaviridae Infections | 1 | 2014 | 3 | 0.410 |
Why?
| | Metapneumovirus | 2 | 2025 | 15 | 0.410 |
Why?
| | Motor Neurons | 1 | 2016 | 236 | 0.410 |
Why?
| | Rubulavirus Infections | 1 | 2013 | 2 | 0.410 |
Why?
| | Whole Genome Sequencing | 1 | 2015 | 184 | 0.400 |
Why?
| | Haemophilus Infections | 2 | 2024 | 45 | 0.400 |
Why?
| | Herpesviridae Infections | 1 | 2015 | 149 | 0.400 |
Why?
| | Coronary Artery Disease | 3 | 2018 | 760 | 0.390 |
Why?
| | Prevalence | 7 | 2025 | 2855 | 0.390 |
Why?
| | Fever | 6 | 2022 | 317 | 0.390 |
Why?
| | Neuraminidase | 3 | 2020 | 25 | 0.380 |
Why?
| | Arthritis, Infectious | 2 | 2026 | 75 | 0.370 |
Why?
| | Coronavirus NL63, Human | 1 | 2012 | 3 | 0.370 |
Why?
| | Betacoronavirus | 3 | 2020 | 288 | 0.360 |
Why?
| | Genotype | 4 | 2017 | 1853 | 0.360 |
Why?
| | Sepsis | 1 | 2018 | 661 | 0.360 |
Why?
| | Viral Load | 3 | 2024 | 528 | 0.350 |
Why?
| | Metagenomics | 5 | 2021 | 184 | 0.350 |
Why?
| | Viral Envelope Proteins | 1 | 2012 | 98 | 0.350 |
Why?
| | Treatment Outcome | 11 | 2026 | 11831 | 0.350 |
Why?
| | Recombination, Genetic | 1 | 2012 | 205 | 0.340 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 171 | 0.330 |
Why?
| | Genetic Variation | 2 | 2014 | 988 | 0.320 |
Why?
| | Cluster Analysis | 5 | 2021 | 517 | 0.320 |
Why?
| | Coinfection | 3 | 2022 | 144 | 0.310 |
Why?
| | Meningitis, Aseptic | 2 | 2020 | 13 | 0.310 |
Why?
| | Young Adult | 17 | 2024 | 14192 | 0.300 |
Why?
| | Rodentia | 7 | 2010 | 62 | 0.300 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 496 | 0.300 |
Why?
| | Infection Control | 2 | 2025 | 174 | 0.300 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 686 | 0.300 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1188 | 0.290 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2910 | 0.270 |
Why?
| | beta-Lactamases | 2 | 2025 | 53 | 0.270 |
Why?
| | Virus Internalization | 4 | 2017 | 65 | 0.270 |
Why?
| | Genome, Microbial | 2 | 2019 | 7 | 0.270 |
Why?
| | Critical Care | 4 | 2021 | 703 | 0.260 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 5891 | 0.260 |
Why?
| | Immunity, Innate | 1 | 2013 | 846 | 0.250 |
Why?
| | Neoplasms | 3 | 2023 | 2897 | 0.250 |
Why?
| | Diagnosis, Differential | 7 | 2020 | 1507 | 0.250 |
Why?
| | Severity of Illness Index | 4 | 2024 | 2945 | 0.250 |
Why?
| | Algorithms | 4 | 2025 | 1855 | 0.250 |
Why?
| | Mycoplasma hominis | 1 | 2006 | 4 | 0.250 |
Why?
| | Gentian Violet | 1 | 2026 | 4 | 0.240 |
Why?
| | Phenazines | 1 | 2026 | 17 | 0.240 |
Why?
| | HIV Infections | 5 | 2017 | 3189 | 0.240 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3424 | 0.240 |
Why?
| | Apolipoproteins E | 4 | 2016 | 94 | 0.240 |
Why?
| | Endocarditis, Bacterial | 1 | 2006 | 46 | 0.240 |
Why?
| | Murine hepatitis virus | 2 | 2016 | 16 | 0.230 |
Why?
| | Immunization | 2 | 2004 | 375 | 0.230 |
Why?
| | Integrons | 1 | 2025 | 4 | 0.230 |
Why?
| | Paramyxoviridae Infections | 1 | 2025 | 12 | 0.230 |
Why?
| | Visitors to Patients | 1 | 2025 | 11 | 0.220 |
Why?
| | Enzyme Inhibitors | 3 | 2020 | 821 | 0.220 |
Why?
| | Critical Illness | 2 | 2025 | 901 | 0.210 |
Why?
| | Paraplegia | 2 | 2015 | 60 | 0.210 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 128 | 0.210 |
Why?
| | Masks | 1 | 2025 | 70 | 0.210 |
Why?
| | Methicillin Resistance | 1 | 2004 | 17 | 0.210 |
Why?
| | DNA, Bacterial | 1 | 2026 | 347 | 0.210 |
Why?
| | Cellulitis | 1 | 2004 | 54 | 0.210 |
Why?
| | Guatemala | 1 | 2025 | 344 | 0.200 |
Why?
| | Meningitis, Haemophilus | 1 | 2003 | 6 | 0.200 |
Why?
| | Haemophilus influenzae type b | 1 | 2003 | 12 | 0.200 |
Why?
| | ROC Curve | 1 | 2026 | 619 | 0.200 |
Why?
| | Haemophilus Vaccines | 1 | 2003 | 29 | 0.200 |
Why?
| | Amoxicillin | 1 | 2024 | 35 | 0.200 |
Why?
| | Musculoskeletal Diseases | 1 | 2025 | 90 | 0.200 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 553 | 0.200 |
Why?
| | Antigens, Viral | 3 | 2020 | 182 | 0.200 |
Why?
| | Clindamycin | 2 | 2018 | 14 | 0.200 |
Why?
| | Polysaccharides, Bacterial | 1 | 2003 | 69 | 0.200 |
Why?
| | Global Health | 2 | 2021 | 404 | 0.190 |
Why?
| | Clinical Laboratory Techniques | 2 | 2020 | 97 | 0.190 |
Why?
| | Risk Factors | 9 | 2021 | 10874 | 0.190 |
Why?
| | American Heart Association | 1 | 2024 | 360 | 0.190 |
Why?
| | Incidence | 4 | 2021 | 2915 | 0.190 |
Why?
| | Hepatitis C | 4 | 2006 | 257 | 0.190 |
Why?
| | Coronavirus 229E, Human | 1 | 2022 | 7 | 0.190 |
Why?
| | Medical Oncology | 2 | 2023 | 338 | 0.180 |
Why?
| | Critical Pathways | 1 | 2024 | 108 | 0.180 |
Why?
| | Disease Management | 3 | 2024 | 654 | 0.180 |
Why?
| | Canada | 3 | 2025 | 434 | 0.180 |
Why?
| | Logistic Models | 2 | 2018 | 2130 | 0.180 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 68 | 0.180 |
Why?
| | Pharyngitis | 1 | 2022 | 25 | 0.180 |
Why?
| | Vomiting | 2 | 2020 | 132 | 0.170 |
Why?
| | Antibodies, Viral | 4 | 2025 | 673 | 0.170 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2020 | 34 | 0.170 |
Why?
| | North America | 2 | 2016 | 312 | 0.170 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 850 | 0.170 |
Why?
| | Abdominal Pain | 2 | 2020 | 149 | 0.170 |
Why?
| | Brain Diseases | 2 | 2020 | 153 | 0.170 |
Why?
| | Meningoencephalitis | 2 | 2019 | 24 | 0.170 |
Why?
| | Lethargy | 1 | 2020 | 4 | 0.170 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 39 | 0.160 |
Why?
| | Lung | 1 | 2014 | 4103 | 0.160 |
Why?
| | Arbovirus Infections | 1 | 2020 | 20 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 4 | 2018 | 3897 | 0.160 |
Why?
| | Intestinal Diseases | 1 | 2020 | 43 | 0.160 |
Why?
| | Peptide Fragments | 3 | 1999 | 693 | 0.160 |
Why?
| | Databases, Factual | 2 | 2025 | 1500 | 0.160 |
Why?
| | Meningitis, Viral | 1 | 2020 | 20 | 0.160 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 975 | 0.160 |
Why?
| | Animals | 23 | 2022 | 38141 | 0.160 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2020 | 21 | 0.160 |
Why?
| | Circulating MicroRNA | 1 | 2020 | 26 | 0.160 |
Why?
| | Influenza Vaccines | 1 | 2005 | 533 | 0.160 |
Why?
| | Medical Records | 2 | 2018 | 192 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2021 | 202 | 0.150 |
Why?
| | Myositis | 1 | 2020 | 57 | 0.150 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2020 | 50 | 0.150 |
Why?
| | Echocardiography | 3 | 2026 | 648 | 0.150 |
Why?
| | Exanthema Subitum | 1 | 2019 | 3 | 0.150 |
Why?
| | Consciousness Disorders | 1 | 2019 | 25 | 0.150 |
Why?
| | Epithelial Cells | 3 | 2015 | 1112 | 0.150 |
Why?
| | Length of Stay | 3 | 2020 | 1348 | 0.150 |
Why?
| | Amino Acid Sequence | 5 | 2016 | 2137 | 0.150 |
Why?
| | Hepatitis | 1 | 2019 | 43 | 0.150 |
Why?
| | Receptors, Lipoprotein | 1 | 1999 | 15 | 0.150 |
Why?
| | Machine Learning | 1 | 2025 | 590 | 0.140 |
Why?
| | Taenia solium | 1 | 2018 | 5 | 0.140 |
Why?
| | Adult | 20 | 2023 | 40707 | 0.140 |
Why?
| | Neurocysticercosis | 1 | 2018 | 8 | 0.140 |
Why?
| | Follow-Up Studies | 5 | 2017 | 5426 | 0.140 |
Why?
| | Immunoglobulin G | 2 | 2020 | 890 | 0.140 |
Why?
| | Abdomen | 1 | 2019 | 142 | 0.140 |
Why?
| | HEK293 Cells | 3 | 2016 | 743 | 0.140 |
Why?
| | Heart Defects, Congenital | 1 | 2006 | 909 | 0.140 |
Why?
| | Vero Cells | 2 | 2015 | 84 | 0.140 |
Why?
| | Methyltransferases | 1 | 2018 | 75 | 0.140 |
Why?
| | Body Fluids | 1 | 2018 | 71 | 0.140 |
Why?
| | Hepacivirus | 3 | 2017 | 244 | 0.140 |
Why?
| | Sequence Alignment | 2 | 2016 | 371 | 0.130 |
Why?
| | Lipoproteins | 1 | 1999 | 166 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 245 | 0.130 |
Why?
| | Microscopy, Electron | 4 | 2015 | 413 | 0.130 |
Why?
| | Receptors, Immunologic | 1 | 1999 | 206 | 0.130 |
Why?
| | Chlamydophila pneumoniae | 1 | 2017 | 12 | 0.130 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.130 |
Why?
| | Mycoplasma Infections | 1 | 2017 | 17 | 0.130 |
Why?
| | Fluorenes | 1 | 2017 | 46 | 0.130 |
Why?
| | Chronic Disease | 1 | 2023 | 1816 | 0.130 |
Why?
| | Sofosbuvir | 1 | 2017 | 61 | 0.130 |
Why?
| | Stomach | 1 | 2017 | 111 | 0.130 |
Why?
| | Mouth Mucosa | 1 | 2017 | 87 | 0.130 |
Why?
| | Intubation, Gastrointestinal | 1 | 2017 | 81 | 0.130 |
Why?
| | Prognosis | 2 | 2016 | 4323 | 0.120 |
Why?
| | Densovirus | 1 | 2016 | 3 | 0.120 |
Why?
| | Organ Transplantation | 1 | 2020 | 251 | 0.120 |
Why?
| | Tristetraprolin | 1 | 2016 | 8 | 0.120 |
Why?
| | Muscular Diseases | 1 | 2017 | 108 | 0.120 |
Why?
| | Movement Disorders | 1 | 2017 | 70 | 0.120 |
Why?
| | Antibodies, Monoclonal | 2 | 2015 | 1511 | 0.120 |
Why?
| | Intensive Care Units | 2 | 2015 | 925 | 0.120 |
Why?
| | Benzimidazoles | 1 | 2017 | 187 | 0.120 |
Why?
| | Middle East Respiratory Syndrome Coronavirus | 1 | 2016 | 11 | 0.120 |
Why?
| | Inflammation | 2 | 2018 | 2883 | 0.120 |
Why?
| | Encephalomyelitis | 1 | 2016 | 14 | 0.120 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2016 | 22 | 0.120 |
Why?
| | Protein Phosphatase 2 | 1 | 2016 | 41 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 2 | 2017 | 497 | 0.120 |
Why?
| | Vaccination | 1 | 2005 | 1423 | 0.120 |
Why?
| | Borderline Personality Disorder | 1 | 2016 | 14 | 0.120 |
Why?
| | Urban Population | 1 | 2019 | 494 | 0.120 |
Why?
| | Electromyography | 2 | 2017 | 419 | 0.120 |
Why?
| | Gastrostomy | 1 | 2017 | 130 | 0.120 |
Why?
| | Balamuthia mandrillaris | 1 | 2015 | 4 | 0.120 |
Why?
| | Amebiasis | 1 | 2015 | 5 | 0.120 |
Why?
| | Still's Disease, Adult-Onset | 1 | 1995 | 5 | 0.120 |
Why?
| | Stomach Ulcer | 1 | 1995 | 12 | 0.120 |
Why?
| | Syncope | 1 | 2016 | 56 | 0.120 |
Why?
| | Cells, Cultured | 2 | 2014 | 4127 | 0.120 |
Why?
| | Hepatitis C, Chronic | 1 | 2017 | 153 | 0.120 |
Why?
| | Dendritic Spines | 1 | 2016 | 70 | 0.120 |
Why?
| | Psychopathology | 1 | 2016 | 55 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 271 | 0.120 |
Why?
| | Bradycardia | 1 | 2016 | 62 | 0.120 |
Why?
| | Genome, Mitochondrial | 1 | 2015 | 29 | 0.110 |
Why?
| | Seizures | 1 | 2020 | 482 | 0.110 |
Why?
| | Early Diagnosis | 1 | 2016 | 251 | 0.110 |
Why?
| | Lyme Disease | 1 | 2016 | 58 | 0.110 |
Why?
| | Madin Darby Canine Kidney Cells | 1 | 2015 | 17 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2023 | 831 | 0.110 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 265 | 0.110 |
Why?
| | Cephalosporins | 1 | 2015 | 48 | 0.110 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 23 | 0.110 |
Why?
| | Sapovirus | 1 | 2015 | 1 | 0.110 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 442 | 0.110 |
Why?
| | Rotavirus | 1 | 2015 | 21 | 0.110 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 138 | 0.110 |
Why?
| | Peritonitis | 1 | 1995 | 83 | 0.110 |
Why?
| | Colonoscopy | 1 | 2017 | 262 | 0.110 |
Why?
| | Norovirus | 1 | 2015 | 22 | 0.110 |
Why?
| | Virus Shedding | 1 | 2015 | 48 | 0.110 |
Why?
| | Mother-Child Relations | 1 | 2016 | 132 | 0.110 |
Why?
| | Bacterial Proteins | 2 | 2018 | 991 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1081 | 0.110 |
Why?
| | Health Resources | 1 | 2016 | 130 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2015 | 162 | 0.110 |
Why?
| | Bacterial Shedding | 1 | 2014 | 3 | 0.110 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 114 | 0.110 |
Why?
| | Zanamivir | 1 | 2014 | 2 | 0.100 |
Why?
| | Drug Therapy, Combination | 3 | 2013 | 1046 | 0.100 |
Why?
| | Rural Population | 1 | 2019 | 658 | 0.100 |
Why?
| | Recurrence | 1 | 2017 | 1142 | 0.100 |
Why?
| | Oseltamivir | 1 | 2014 | 17 | 0.100 |
Why?
| | Cost of Illness | 1 | 2016 | 324 | 0.100 |
Why?
| | Parainfluenza Virus 4, Human | 1 | 2013 | 2 | 0.100 |
Why?
| | Dogs | 1 | 2015 | 438 | 0.100 |
Why?
| | Republic of Korea | 2 | 2025 | 43 | 0.100 |
Why?
| | Molecular Typing | 1 | 2013 | 21 | 0.100 |
Why?
| | Anomie | 1 | 2013 | 3 | 0.100 |
Why?
| | RNA Viruses | 1 | 2015 | 76 | 0.100 |
Why?
| | Giant Cells | 1 | 2013 | 21 | 0.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 700 | 0.100 |
Why?
| | Disease Reservoirs | 1 | 2013 | 25 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 344 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2016 | 456 | 0.100 |
Why?
| | Stress Disorders, Traumatic | 1 | 2013 | 25 | 0.100 |
Why?
| | Particulate Matter | 1 | 2016 | 337 | 0.100 |
Why?
| | Brazil | 1 | 2013 | 183 | 0.100 |
Why?
| | Social Adjustment | 1 | 2013 | 64 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 873 | 0.100 |
Why?
| | Pediatrics | 3 | 2020 | 1121 | 0.100 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 172 | 0.090 |
Why?
| | Mexico | 1 | 2013 | 234 | 0.090 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 322 | 0.090 |
Why?
| | Membrane Proteins | 1 | 1999 | 1164 | 0.090 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 40 | 0.090 |
Why?
| | Age Factors | 4 | 2010 | 3340 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2013 | 531 | 0.090 |
Why?
| | Middle Aged | 17 | 2020 | 36176 | 0.090 |
Why?
| | Neuroimaging | 1 | 2014 | 293 | 0.090 |
Why?
| | Oxygen | 2 | 2023 | 986 | 0.090 |
Why?
| | Treatment Failure | 1 | 2013 | 365 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 394 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 251 | 0.090 |
Why?
| | Environmental Exposure | 1 | 2016 | 577 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 681 | 0.090 |
Why?
| | Biomarkers | 3 | 2021 | 4283 | 0.090 |
Why?
| | Models, Theoretical | 2 | 2025 | 579 | 0.090 |
Why?
| | Brain | 3 | 2018 | 2944 | 0.080 |
Why?
| | Illinois | 2 | 2015 | 49 | 0.080 |
Why?
| | Antibodies, Neutralizing | 1 | 2014 | 342 | 0.080 |
Why?
| | Bulbourethral Glands | 1 | 2010 | 1 | 0.080 |
Why?
| | Seminal Vesicles | 1 | 2010 | 9 | 0.080 |
Why?
| | Inpatients | 1 | 2015 | 550 | 0.080 |
Why?
| | Liver Function Tests | 1 | 2011 | 105 | 0.080 |
Why?
| | Urogenital System | 1 | 2010 | 17 | 0.080 |
Why?
| | Intestines | 1 | 2013 | 357 | 0.080 |
Why?
| | Macrophages, Alveolar | 1 | 2013 | 368 | 0.080 |
Why?
| | Peptides | 1 | 2016 | 993 | 0.080 |
Why?
| | Mothers | 1 | 2016 | 767 | 0.080 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 774 | 0.080 |
Why?
| | Aspirin | 1 | 2013 | 407 | 0.070 |
Why?
| | Cell Line | 5 | 2017 | 2823 | 0.070 |
Why?
| | Prostate | 1 | 2010 | 158 | 0.070 |
Why?
| | Receptors, Androgen | 1 | 2010 | 148 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2013 | 772 | 0.070 |
Why?
| | Cholesteatoma | 1 | 1988 | 10 | 0.070 |
Why?
| | Ear Diseases | 1 | 1988 | 19 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 1993 | 1965 | 0.070 |
Why?
| | Mental Health Services | 1 | 2013 | 472 | 0.070 |
Why?
| | Disease Transmission, Infectious | 2 | 2005 | 69 | 0.070 |
Why?
| | Liver Diseases | 1 | 2011 | 304 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1993 | 644 | 0.070 |
Why?
| | Head and Neck Neoplasms | 1 | 1993 | 562 | 0.070 |
Why?
| | Adrenal Medulla | 1 | 2007 | 10 | 0.070 |
Why?
| | Chromaffin Cells | 1 | 2007 | 4 | 0.070 |
Why?
| | Cleft Palate | 1 | 1988 | 90 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2016 | 1153 | 0.060 |
Why?
| | Lipoproteins, LDL | 2 | 1999 | 119 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 1 | 2016 | 1177 | 0.060 |
Why?
| | Mice | 8 | 2022 | 18338 | 0.060 |
Why?
| | Diagnostic Errors | 1 | 2008 | 179 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1794 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 782 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 2006 | 70 | 0.060 |
Why?
| | Patient Admission | 1 | 2008 | 221 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1993 | 1150 | 0.060 |
Why?
| | Odds Ratio | 2 | 2021 | 1082 | 0.060 |
Why?
| | Scotland | 1 | 2025 | 23 | 0.060 |
Why?
| | Argentina | 1 | 2025 | 30 | 0.060 |
Why?
| | Photoperiod | 2 | 2010 | 55 | 0.060 |
Why?
| | Immunoassay | 1 | 2006 | 108 | 0.060 |
Why?
| | Serogroup | 1 | 2025 | 45 | 0.060 |
Why?
| | Sexually Transmitted Diseases, Viral | 1 | 2005 | 11 | 0.060 |
Why?
| | Klebsiella pneumoniae | 1 | 2025 | 47 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 2019 | 607 | 0.060 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2025 | 81 | 0.050 |
Why?
| | Chicago | 1 | 2004 | 63 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 2 | 2020 | 482 | 0.050 |
Why?
| | Population Surveillance | 1 | 2008 | 485 | 0.050 |
Why?
| | Homosexuality | 1 | 2004 | 17 | 0.050 |
Why?
| | Aged | 8 | 2020 | 26125 | 0.050 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.050 |
Why?
| | Models, Molecular | 3 | 2017 | 1614 | 0.050 |
Why?
| | Fibroblasts | 3 | 2016 | 1023 | 0.050 |
Why?
| | Base Sequence | 1 | 2007 | 2180 | 0.050 |
Why?
| | Bacterial Capsules | 1 | 2003 | 33 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2772 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2005 | 232 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2129 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 270 | 0.050 |
Why?
| | Streptococcus | 1 | 2023 | 29 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2023 | 339 | 0.050 |
Why?
| | Risk Assessment | 2 | 2019 | 3759 | 0.050 |
Why?
| | Minnesota | 1 | 2023 | 170 | 0.050 |
Why?
| | Respiratory System | 1 | 2023 | 151 | 0.050 |
Why?
| | Immunization Schedule | 1 | 2003 | 186 | 0.050 |
Why?
| | Computational Biology | 2 | 2019 | 687 | 0.050 |
Why?
| | Heparin Lyase | 2 | 1999 | 5 | 0.040 |
Why?
| | Data Collection | 1 | 2005 | 639 | 0.040 |
Why?
| | Immunologic Surveillance | 1 | 2022 | 25 | 0.040 |
Why?
| | Immunization Programs | 1 | 2003 | 193 | 0.040 |
Why?
| | New Zealand | 1 | 2021 | 55 | 0.040 |
Why?
| | Italy | 1 | 2021 | 114 | 0.040 |
Why?
| | History, 21st Century | 1 | 2022 | 220 | 0.040 |
Why?
| | Embryo, Mammalian | 2 | 1999 | 234 | 0.040 |
Why?
| | Schools | 1 | 2004 | 453 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2021 | 153 | 0.040 |
Why?
| | Sertoli Cells | 1 | 2001 | 28 | 0.040 |
Why?
| | Conserved Sequence | 2 | 1998 | 247 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 83 | 0.040 |
Why?
| | Nucleocapsid Proteins | 1 | 2020 | 28 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 282 | 0.040 |
Why?
| | Oropharynx | 1 | 2020 | 46 | 0.040 |
Why?
| | Serologic Tests | 1 | 2020 | 54 | 0.040 |
Why?
| | Societies, Medical | 1 | 2005 | 898 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2020 | 90 | 0.040 |
Why?
| | Receptors, LDL | 2 | 1998 | 53 | 0.040 |
Why?
| | Lithium | 1 | 2000 | 40 | 0.040 |
Why?
| | Discriminant Analysis | 1 | 2020 | 35 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 103 | 0.040 |
Why?
| | Comorbidity | 2 | 2021 | 1659 | 0.040 |
Why?
| | Confusion | 1 | 2020 | 30 | 0.040 |
Why?
| | Macrophages | 2 | 2016 | 1509 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 136 | 0.040 |
Why?
| | Anti-Ulcer Agents | 1 | 1999 | 12 | 0.040 |
Why?
| | Adrenal Cortex | 1 | 1999 | 33 | 0.040 |
Why?
| | Testis | 1 | 2000 | 162 | 0.040 |
Why?
| | Spermatozoa | 1 | 2000 | 108 | 0.040 |
Why?
| | Sesquiterpenes | 1 | 1999 | 52 | 0.040 |
Why?
| | Chlorates | 1 | 1999 | 4 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2000 | 148 | 0.040 |
Why?
| | Immunocompetence | 1 | 2019 | 46 | 0.040 |
Why?
| | Scavenger Receptors, Class A | 1 | 1999 | 12 | 0.040 |
Why?
| | Scavenger Receptors, Class B | 1 | 1999 | 14 | 0.040 |
Why?
| | Egtazic Acid | 1 | 1999 | 37 | 0.040 |
Why?
| | Reproduction | 1 | 2001 | 207 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 848 | 0.040 |
Why?
| | Receptors, Scavenger | 1 | 1999 | 22 | 0.040 |
Why?
| | Picornaviridae | 1 | 2019 | 18 | 0.040 |
Why?
| | Lactones | 1 | 1999 | 59 | 0.040 |
Why?
| | Infant, Newborn, Diseases | 1 | 2020 | 115 | 0.040 |
Why?
| | Antibodies, Helminth | 1 | 2018 | 6 | 0.040 |
Why?
| | Parasites | 1 | 2019 | 44 | 0.040 |
Why?
| | Seminiferous Epithelium | 1 | 1998 | 1 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2019 | 116 | 0.040 |
Why?
| | Europe | 1 | 2020 | 421 | 0.040 |
Why?
| | Lactams | 1 | 1998 | 28 | 0.040 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 194 | 0.040 |
Why?
| | Blood | 1 | 1999 | 107 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 422 | 0.040 |
Why?
| | Plasma | 1 | 2020 | 225 | 0.040 |
Why?
| | Lipoproteins, HDL | 1 | 1999 | 99 | 0.040 |
Why?
| | Child Health Services | 1 | 2020 | 185 | 0.030 |
Why?
| | Drug Resistance | 1 | 2019 | 146 | 0.030 |
Why?
| | Health Personnel | 1 | 2005 | 750 | 0.030 |
Why?
| | Spermatogenesis | 1 | 1998 | 91 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2020 | 339 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2020 | 180 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2018 | 316 | 0.030 |
Why?
| | Patient Discharge | 1 | 2025 | 992 | 0.030 |
Why?
| | Evolution, Molecular | 2 | 2016 | 518 | 0.030 |
Why?
| | Arboviruses | 1 | 2017 | 14 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 170 | 0.030 |
Why?
| | Models, Biological | 1 | 2025 | 1815 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 320 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2950 | 0.030 |
Why?
| | Headache | 1 | 2018 | 151 | 0.030 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 46 | 0.030 |
Why?
| | Models, Chemical | 1 | 1999 | 264 | 0.030 |
Why?
| | Structural Homology, Protein | 1 | 2017 | 23 | 0.030 |
Why?
| | Genes, Bacterial | 1 | 2018 | 170 | 0.030 |
Why?
| | HIV Protease Inhibitors | 1 | 2017 | 69 | 0.030 |
Why?
| | Contact Tracing | 1 | 2017 | 26 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 2018 | 109 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 411 | 0.030 |
Why?
| | Epitope Mapping | 1 | 2017 | 61 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 92 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2017 | 104 | 0.030 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2016 | 7 | 0.030 |
Why?
| | Macrolides | 1 | 2017 | 69 | 0.030 |
Why?
| | RNA | 1 | 2023 | 929 | 0.030 |
Why?
| | Colon | 1 | 1999 | 308 | 0.030 |
Why?
| | Amino Alcohols | 1 | 2016 | 2 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 863 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 208 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2018 | 193 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 443 | 0.030 |
Why?
| | Paracentesis | 1 | 1996 | 16 | 0.030 |
Why?
| | Genomics | 1 | 2022 | 834 | 0.030 |
Why?
| | Atrophy | 1 | 2017 | 199 | 0.030 |
Why?
| | Sequence Homology | 1 | 2016 | 44 | 0.030 |
Why?
| | Clinical Competence | 1 | 2005 | 1242 | 0.030 |
Why?
| | Colitis | 1 | 1999 | 280 | 0.030 |
Why?
| | Ascites | 1 | 1996 | 48 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2016 | 82 | 0.030 |
Why?
| | Eosinophilia | 1 | 2018 | 223 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 16 | 0.030 |
Why?
| | Membrane Fusion | 1 | 2016 | 41 | 0.030 |
Why?
| | Urban Health | 1 | 2016 | 96 | 0.030 |
Why?
| | Dextrans | 1 | 1996 | 87 | 0.030 |
Why?
| | Pyramidal Cells | 1 | 2016 | 80 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2019 | 505 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 207 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2016 | 131 | 0.030 |
Why?
| | Serine | 1 | 2016 | 144 | 0.030 |
Why?
| | Naproxen | 1 | 1995 | 21 | 0.030 |
Why?
| | Prednisolone | 1 | 1995 | 66 | 0.030 |
Why?
| | Missouri | 1 | 2015 | 66 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2017 | 491 | 0.030 |
Why?
| | Facial Expression | 1 | 2016 | 74 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 314 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 565 | 0.030 |
Why?
| | Synovial Membrane | 1 | 2016 | 124 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 551 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2030 | 0.030 |
Why?
| | Respiratory Sounds | 1 | 2015 | 103 | 0.030 |
Why?
| | Epitopes | 1 | 2017 | 480 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 146 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 402 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 762 | 0.030 |
Why?
| | Systole | 1 | 2015 | 181 | 0.030 |
Why?
| | Cough | 1 | 2015 | 123 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 306 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2016 | 210 | 0.030 |
Why?
| | Cote d'Ivoire | 1 | 2014 | 9 | 0.030 |
Why?
| | beta Catenin | 1 | 2016 | 253 | 0.030 |
Why?
| | Vietnam | 1 | 2014 | 29 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 357 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 1996 | 287 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 98 | 0.030 |
Why?
| | Social Behavior | 1 | 2016 | 288 | 0.030 |
Why?
| | Protein Binding | 2 | 2017 | 2250 | 0.030 |
Why?
| | Biodiversity | 1 | 2018 | 429 | 0.030 |
Why?
| | Gene Order | 1 | 2013 | 28 | 0.030 |
Why?
| | Liberia | 1 | 2013 | 15 | 0.030 |
Why?
| | Social Control, Formal | 1 | 2013 | 10 | 0.030 |
Why?
| | Cell Membrane | 2 | 2013 | 707 | 0.030 |
Why?
| | Dyspnea | 1 | 2015 | 250 | 0.020 |
Why?
| | Lentivirus | 1 | 2013 | 61 | 0.020 |
Why?
| | Trypsin | 1 | 2013 | 75 | 0.020 |
Why?
| | Kidney | 1 | 2021 | 1498 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 439 | 0.020 |
Why?
| | California | 1 | 2015 | 483 | 0.020 |
Why?
| | Depressive Disorder | 1 | 2016 | 387 | 0.020 |
Why?
| | Anxiety Disorders | 1 | 2016 | 370 | 0.020 |
Why?
| | Mesna | 1 | 1993 | 15 | 0.020 |
Why?
| | Ifosfamide | 1 | 1993 | 39 | 0.020 |
Why?
| | Alopecia | 1 | 1993 | 37 | 0.020 |
Why?
| | Warfare | 1 | 2013 | 99 | 0.020 |
Why?
| | Synapses | 1 | 2016 | 438 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1585 | 0.020 |
Why?
| | Exanthema | 1 | 2013 | 86 | 0.020 |
Why?
| | Endosomes | 1 | 2013 | 140 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1755 | 0.020 |
Why?
| | Vulnerable Populations | 1 | 2013 | 175 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1707 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 563 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 392 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1896 | 0.020 |
Why?
| | HIV-1 | 1 | 2017 | 905 | 0.020 |
Why?
| | Nausea | 1 | 1992 | 113 | 0.020 |
Why?
| | Antiemetics | 1 | 1992 | 51 | 0.020 |
Why?
| | gamma-Glutamyltransferase | 1 | 2011 | 42 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2011 | 85 | 0.020 |
Why?
| | Bilirubin | 1 | 2011 | 99 | 0.020 |
Why?
| | Pregnancy | 2 | 2020 | 7197 | 0.020 |
Why?
| | Needs Assessment | 1 | 2013 | 401 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1332 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2011 | 151 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2016 | 866 | 0.020 |
Why?
| | Urethra | 1 | 2010 | 56 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 153 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2379 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 364 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1991 | 124 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 3125 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2146 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 651 | 0.020 |
Why?
| | Iowa | 1 | 1988 | 31 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 1127 | 0.020 |
Why?
| | Otitis Media with Effusion | 1 | 1988 | 20 | 0.020 |
Why?
| | Rats, Wistar | 2 | 2000 | 449 | 0.020 |
Why?
| | Cytokines | 1 | 2016 | 2054 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1478 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2820 | 0.020 |
Why?
| | Capsid Proteins | 1 | 2008 | 93 | 0.020 |
Why?
| | Mental Disorders | 1 | 2016 | 1157 | 0.020 |
Why?
| | Catecholamines | 1 | 2007 | 88 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1573 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2013 | 862 | 0.020 |
Why?
| | Hepatitis C Antigens | 1 | 2006 | 1 | 0.020 |
Why?
| | Hepatitis C Antibodies | 1 | 2006 | 11 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2006 | 199 | 0.010 |
Why?
| | Rats | 3 | 2000 | 5581 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4559 | 0.010 |
Why?
| | Viral Proteins | 1 | 2008 | 353 | 0.010 |
Why?
| | Qualitative Research | 1 | 2013 | 1677 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2006 | 119 | 0.010 |
Why?
| | France | 1 | 2005 | 40 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 5989 | 0.010 |
Why?
| | Sexuality | 1 | 2005 | 32 | 0.010 |
Why?
| | Mutation | 1 | 2016 | 4093 | 0.010 |
Why?
| | Safe Sex | 1 | 2004 | 24 | 0.010 |
Why?
| | Syphilis | 1 | 2004 | 38 | 0.010 |
Why?
| | Asthma | 1 | 2015 | 1795 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1710 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 8326 | 0.010 |
Why?
| | Calcium | 1 | 2007 | 1190 | 0.010 |
Why?
| | Cyclophosphamide | 2 | 1992 | 266 | 0.010 |
Why?
| | Organelles | 1 | 2001 | 58 | 0.010 |
Why?
| | Sperm Motility | 1 | 2000 | 35 | 0.010 |
Why?
| | Cell Count | 1 | 2001 | 320 | 0.010 |
Why?
| | Trinitrobenzenesulfonic Acid | 1 | 1999 | 10 | 0.010 |
Why?
| | Zona Fasciculata | 1 | 1999 | 1 | 0.010 |
Why?
| | Colloids | 1 | 2000 | 60 | 0.010 |
Why?
| | Acetic Acid | 1 | 1999 | 21 | 0.010 |
Why?
| | Irritants | 1 | 1999 | 42 | 0.010 |
Why?
| | Doxorubicin | 2 | 1992 | 398 | 0.010 |
Why?
| | Spermatogonia | 1 | 1998 | 16 | 0.010 |
Why?
| | Melatonin | 1 | 2000 | 163 | 0.010 |
Why?
| | Spermatids | 1 | 1998 | 25 | 0.010 |
Why?
| | Organ Size | 1 | 1999 | 461 | 0.010 |
Why?
| | Circular Dichroism | 1 | 1998 | 144 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1998 | 137 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1998 | 366 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1998 | 567 | 0.010 |
Why?
| | Polysaccharide-Lyases | 1 | 1996 | 11 | 0.010 |
Why?
| | Ascitic Fluid | 1 | 1996 | 15 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 182 | 0.010 |
Why?
| | Half-Life | 1 | 1996 | 153 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1996 | 169 | 0.010 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 1998 | 346 | 0.010 |
Why?
| | Body Weight | 1 | 2000 | 970 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1996 | 1047 | 0.010 |
Why?
| | Reference Values | 1 | 1996 | 797 | 0.010 |
Why?
| | Sex Factors | 1 | 2000 | 2110 | 0.010 |
Why?
| | Protein Conformation | 1 | 1996 | 935 | 0.010 |
Why?
| | Binding Sites | 1 | 1996 | 1313 | 0.010 |
Why?
| | Thiethylperazine | 1 | 1992 | 1 | 0.010 |
Why?
| | Amitriptyline | 1 | 1992 | 24 | 0.010 |
Why?
| | Methylprednisolone | 1 | 1992 | 58 | 0.010 |
Why?
| | Procarbazine | 1 | 1991 | 9 | 0.010 |
Why?
| | Fluorouracil | 1 | 1992 | 235 | 0.010 |
Why?
| | Leucovorin | 1 | 1991 | 101 | 0.010 |
Why?
| | Neurons | 1 | 2000 | 1647 | 0.010 |
Why?
| | Etoposide | 1 | 1991 | 168 | 0.000 |
Why?
| | Vincristine | 1 | 1991 | 140 | 0.000 |
Why?
| | Prednisone | 1 | 1991 | 221 | 0.000 |
Why?
| | Methotrexate | 1 | 1991 | 232 | 0.000 |
Why?
| | Liver | 1 | 1996 | 1895 | 0.000 |
Why?
|
|
Dominguez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|